UNSPSC 51372013: Thebacon

This classification denotes an opioid receptor agonist with the molecular formula C20H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 520D430GDK, chemically known as thebaine, demethyldihydro-, acetate (ester) but generally known as thebacon, which bears US NIH Compound Identifier 10075. European Medicines Agency schedules Thebacon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10959MIG. The term THEBACON is an International Non-Proprietary Name.

UNSPSC 51372013 Thebacon is a Commodity code under which state and local governments procure naloxone, pharmaceutical products, and over-the-counter health supplies through direct-purchase and cooperative purchasing channels. Recent activity shows procurement officers soliciting naloxone and drug deactivation systems for community health initiatives, generic pharmaceuticals and OTC products through multistate cooperative agreements, and exploring direct-to-manufacturer prescription fulfillment models. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). The code reflects a mix of tactical procurement—consumable medical supplies for immediate operational needs—and strategic sourcing aimed at cost management and supply-chain efficiency across government-wide vendor networks.

Geographic activity centers on Florida and Texas, with multistate participation through cooperative purchasing vehicles serving Oregon, Minnesota, and other participating jurisdictions. Recent representative opportunities include Seminole County's IFB60459723LAS, an invitation for bids posted June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a response deadline of July 26, 2023; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and MMCAP's RFP S1070000015802, issued January 20, 2026, to establish contracts for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, and contract effectiveness July 1, 2026. Cooperative purchasing agreements typically require vendors to comply with cGMP and Drug Supply Chain Security Act standards, maintain relationships with authorized wholesalers, and submit pricing in fixed, net-price, or WAC-minus formats; performance penalties and 3 percent administrative fees apply under multistate arrangements.